TrumpRx is here. Here's how it may impact your clinic and the future of Pharma
Industry Buzz
On the surface [it] sounds promising, but the question is, what medications are gonna be on this website? And is this going to actually undercut prices if you are already insured by Medicare, Medicaid, or private insurance?
—Zachary Rubin, MD, allergist and immunologist, @rubin_allergy
He's destroying health insurance, implementing drug tariffs, then opening his own pharmacy to grift the people who he made unable to afford healthcare. It's total corruption.
—MD on Reddit @somehugefrigginguyt
If there’s one thing Americans can probably agree on, it’s that healthcare is costing us an arm and a leg. According to the White House, approximately “75% of global pharmaceutical profits come from American taxpayers,” despite the fact that the US accounts for less than 5% of the world’s population.[]
As of the evening of February 5, TrumpRx has officially launched. TrumpRx is a government-run prescription drug pricing portal that claims it will help patients find discounted medications by connecting them with direct-to-consumer (DTC) pricing options. Unlike some early descriptions, TrumpRx will not sell medications directly from a government store. Instead, it is a cash-pay drug pricing portal that publishes discounted prices negotiated with manufacturers and redirects users to private purchasing platforms, including manufacturers’ own DTC sites, so patients can complete purchases there.
Pfizer was one of the first major companies to strike a pricing deal and committed to offering many of its drugs through TrumpRx at marked-down prices, with some discounts reportedly as high as 85% off list price.[] Previous news reports noted that Pfizer would then be forced to rely on a greater revenue share from countries abroad (or eat the lost profits). As part of the deal, Pfizer was granted a 3-year tariff-free grace period to relocate some of its production and manufacturing facilities to the US.[]
What will TrumpRx do for your patients?
According to the White House, over 100 million Americans are impacted by diseases that are treated with Pfizer’s medications.[] But with several breakthrough therapies still under patent, patients are often left with the decision to pay top dollar or forgo treatment. Clinicians feel their patients' pain, but their hands are tied when it comes to cost.
Patients who do have insurance (that is, the vast majority of the population) might see limited benefit with TrumpRx if their existing plans already offer competitive pricing. For clinicians, the hope is that even modest out-of-pocket savings could improve adherence for patients struggling to afford medications.
This predicament isn’t new, and it hasn’t shown signs of improvement despite the ever-changing healthcare landscape in the US. TrumpRx should lower costs for the nation’s most vulnerable on Medicaid. However, it’s becoming clearer that that won't necessarily be the case. In fact, the author of an opinion piece in STAT posited that TrumpRx more so offers a “distraction” from exorbitantly high drug prices—not a solution to it.[]
Hot takes from r/medicine
"It sounded to me that it's going to be a 'landing page' of sorts that will point patients to the appropriate already-existing manufacturers' discount programs for fulfillment. At least I'm DESPERATELY hoping that's what it's going to be." —@jvaughnRN, a registered nurse
"He's destroying health insurance, implementing drug tariffs, then opening his own pharmacy to grift the people who he made unable to afford healthcare. It's total corruption." —@somehugefrigginguyt, an MD
Pharmaceutical innovation in a post-TrumpRx world
Nothing drives innovation like high profits. Drugs are a big business, especially in the US. Pressuring drug companies to offer Americans the same deals they provide to patients abroad sure seems like a favorable plan, but we're not getting our hopes up. Consider lawmakers' recent letter to the OIG, which says, "We cannot be sure that TrumpRx will comply with existing federal laws," citing a severe lack of clarity on "how HHS OIG will conduct oversight of a manufacturer’s DTC platform that is embedded in the TrumpRx website."
Nonetheless, the ever-rising cost of healthcare has taken its toll on Americans.[] We’re a nation with access to the most advanced therapies ever produced, but we can’t afford them.
Ultimately, the global impact of a program like TrumpRx is impossible to fully predict. Here’s to hoping that Medicaid patients will get a breather despite inevitable growing pains for the pharmaceutical industry.
Read Next: What the new findings about gabapentin could mean for your practice in 2026